培美曲塞单药维持化疗晚期非小细胞肺癌的疗效观察  

Clinical effect of maintenance chemotherapy by pemetrexed on advanced non-small-cell lung cancer

作　　者：张玉梅[1] 李春姗[1] 陈逸恒[1] 

机构地区：[1]广西中医学院第一附院肿瘤血液内科,广西南宁530023

出　　处：《实用临床医药杂志》2011年第13期48-50,共3页Journal of Clinical Medicine in Practice

摘　　要：目的观察晚期非小细胞肺癌(NSCLC)应用培美曲塞维持化疗的疗效以及对生存时间的影响。方法选择经一线GP(吉西他滨+顺铂)方案化疗4周期后获得疾病控制的晚期NSCIC患者36例,在完成4周期化疗后第21天开始应用培美曲塞维持化疗直至疾病进展,主要观察中位无进展生存期(MPFS)、中位生存期(MST)及不良反应情况。结果 36例晚期NSCLC患者共完成维持化疗153周期,MPFS为4.2个月,MST为9.4个月,主要不良反应为白细胞减少和疲乏,但均可忍受。结论晚期NSCLC患者化疗稳定后应用培美曲塞维持化疗是安全的,并能明显延长患者的无进展生存期,同时不良反应均可耐受。Objective To study the clinical effect of maintenance chemotherapy by pemetrexed in advanced non-small-cell lung cancer.Methods Thirty-six patients of advanced NSCLC who received gemcitabine plus cisplatin achieving disease stabilization（CR/PR/SD） were given pemetrexed maintenance（500 mg/m2 on d1 every 21 days） until progression of disease.MPFS,MST and diverse reactions were observed.Results The cycles of maintenance chemotherapy were 153.MPFS throughout the maintenance period was 4.2 months,and MST was 9.4 months.The main side effects were leucopenia and fatigue which were tolerable.Conclusion Maintenance chemotherapy with pemetrexed following initial therapy with gemcitabine or docetaxel plus cisplatin is feasible.It can extend the PFS,and shows a favorable toxicity profile.

关 键 词：培美曲塞 维持治疗 非小细胞肺癌 

分 类 号：R734.2[医药卫生—肿瘤]